Gleamer SAS reported closing a series B round of $29.6 million to help expand its portfolio of artificial intelligence (AI) systems for radiologists and ramp international expansion. The exercise was led by Supernova Invest SAS who put up $11 million, joined by Heal Capital SAS with $5.5 million.

Biopharmas raising money in public or private financings, including: Ambrx, Axsome, Evommune, Hemostemix, Immutep, Longeveron, Minerva, Moonlake, Sonnet.

Med-tech firms raising money in public or private financings, including: Augmedics, Flywheel, Microbot Medical, Pacific Biosciences, Presidio Medical.

Biopharmas raising money in public or private financings, including:  Contrafect, Foresee, Galderma, Immunogenesis, Immutep, Kinarus, Moonlake.

Edding Group Co. Ltd. announced June 23 it filed for an IPO on the Hong Kong Exchange – news that comes amid a steep drop in China’s biopharma IPO market forecasting sluggish activity in a near-frozen “capital winter.”

The near $50 million cash injection Nvision Imaging Technologies GmbH recently received is “instrumental” as it will allow the company to take its hyperpolarized magnetic resonance imaging (MRI) technology to labs worldwide, CEO Sella Brosh told BioWorld. The German startup’s quantum technology makes MRI imaging up to 100,000 times more precise which will allow for the earlier diagnosis of cancer, better assessment of the risks involved and the ability to assess in a matter of days, whether treatment is working.

Biopharmas raising money in public or private financings, including: Acer, Actimed, Diamedica, Orchard, Oric.

Biopharmas raising money in public or private financings, including: Apogee, Calidi, Disc, Relief.